Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bioventus (BVS)
NASDAQ:BVS
Bioventus (BVS) Stock Price & Analysis
104 Followers
BVS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.86 - $6.08
Previous Close$4.31
Volume41.74K
Average Volume (3M)142.81K
Market Cap
$340.38M
Enterprise Value$746.61M
Total Cash (Recent Filing)$36.96M
Total Debt (Recent Filing)$394.85M
Price to Earnings (P/E)-1.7
Beta0.93
Next Earnings
May 08, 2024EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.51
Shares Outstanding79,165,540
10 Day Avg. Volume140,924
30 Day Avg. Volume142,812
Standard Deviation0.35
R-Squared0.00506
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-1.08
Price to Sales (P/S)0.51
Price to Cash Flow (P/CF)8.20
P/FCF Ratio8.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.46
Enterprise Value/Gross Profit2.27
Enterprise Value/Ebitda-11.03
Forecast
1Y Price Target
$8.00Price Target Upside93.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bioventus News
Ownership Overview
48.16% Insiders
5.25% Mutual Funds
2.43% Other Institutional Investors
44.15% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BVS FAQ
What was Bioventus’s price range in the past 12 months?
Bioventus lowest stock price was $0.86 and its highest was $6.08 in the past 12 months.
What is Bioventus’s market cap?
Currently, no data Available
When is Bioventus’s upcoming earnings report date?
Bioventus’s upcoming earnings report date is May 08, 2024 which is in 13 days.
How were Bioventus’s earnings last quarter?
Bioventus released its earnings results on Mar 12, 2024. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.019 by $0.051.
Is Bioventus overvalued?
According to Wall Street analysts Bioventus’s price is currently Undervalued.
Does Bioventus pay dividends?
Bioventus does not currently pay dividends.
What is Bioventus’s EPS estimate?
Bioventus’s EPS estimate is -$0.07.
How many shares outstanding does Bioventus have?
Bioventus has 63,378,803 shares outstanding.
What happened to Bioventus’s price movement after its last earnings report?
Bioventus reported an EPS of $0.07 in its last earnings report, beating expectations of $0.019. Following the earnings report the stock price went up 5.461%.
Which hedge fund is a major shareholder of Bioventus?
Among the largest hedge funds holding Bioventus’s share is EntryPoint Capital, LLC. It holds Bioventus’s shares valued at 49K.
---
Bioventus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (93.24% Upside)
$8.00 (93.24% Upside)
Blogger Sentiment
Bullish
BVS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 322.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
306.86%
12-Months-Change
Fundamentals
Return on Equity
-39.47%
Trailing 12-Months
Asset Growth
-40.92%
Trailing 12-Months
Company Description
Bioventus
Bioventus Inc is a medical technology company incorporated in Delaware on December 22, 2015. The Company is engaged in developing and commercializing orthobiologic products for the treatment of patients suffering from a broad array of musculoskeletal conditions. Its products address the growing need for clinically effective, cost efficient and minimally invasive solutions that enhance the body's natural healing processes. The Company operates through four segments including Active Healing Therapies-U.S., Active Healing Therapies-International, Surgical and BMP. The Company's Active Healing Therapies segments offer two types of non-surgical products including non-invasive Exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief.
---
BVS Company Deck
---
BVS Earnings Call
Q4 2024
0:00 / 0:00
---
BVS Stock 12 Months Forecast
Average Price Target
$8.00
▲(93.24% Upside)
Technical Analysis
Best Analysts Covering BVS
1 Year
1 Year Success Rate
2/4 ratings generated profit
1 Year Average Return
-7.88%
assigned a buy rating last month
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -7.88% per trade.
---